$0.56
(Market cap
$1,102 Mln
Revenue (TTM)
$32 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-33.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
61,136,773
5 Years Aggregate
CFO
$-118.67 Mln
EBITDA
$-180.42 Mln
Net Profit
$-154.50 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Janux Therapeutics Inc (JANX)
| 40.9 | 28.2 | 35.0 | -14.4 | 20.9 | -9.4 | -- |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Janux Therapeutics Inc (JANX)
| -74.2 | 392.5 | -18.5 | -33.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Janux Therapeutics Inc (JANX)
|
19.5 | 1,102.3 | 31.9 | -102.6 | -252.9 | -10.9 | -- | 1.2 |
| 84.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.2 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.4 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 366.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 543.3 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.3 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 357.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 145.7 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Janux Therapeutics Inc (JANX)
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms... technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Read more
-
President, CEO & Director
Dr. David Alan Campbell Ph.D.
-
President, CEO & Director
Dr. David Alan Campbell Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Janux Therapeutics Inc (JANX)
What is the current share price of Janux Therapeutics Inc (JANX) Today?
The share price of Janux Therapeutics Inc (JANX) is $19.45 (NASDAQ) as of 02-Sep-2026 14:35 EDT. Janux Therapeutics Inc (JANX) has given a return of 20.89% in the last 3 years.
What is the current PB & PE ratio of Janux Therapeutics Inc (JANX)?
Since, TTM earnings of Janux Therapeutics Inc (JANX) is negative, P/E ratio is not available.
The P/B ratio of Janux Therapeutics Inc (JANX) is 1.24 times as on 28-Aug-2026, a 76 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.53 |
0.89 |
2024 |
-44.10 |
2.98 |
2023 |
-8.59 |
1.45 |
2022 |
-10.11 |
1.71 |
2021 |
-24.97 |
2.22 |
What is the 52 Week High and Low of Janux Therapeutics Inc (JANX)?
The 52-week high and low of Janux Therapeutics Inc (JANX) are Rs 35.25 and Rs 12.12 as of 03-Sep-2026.
What is the market cap of Janux Therapeutics Inc (JANX)?
Janux Therapeutics Inc (JANX) has a market capitalisation of $ 1,102 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Janux Therapeutics Inc (JANX)?
Before investing in Janux Therapeutics Inc (JANX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.